How plausible is an Alzheimer’s disease vaccine?
- 17 September 2019
- journal article
- editorial
- Published by Taylor & Francis in Expert Opinion on Drug Discovery
- Vol. 15 (1) , 1-6
Abstract
Introduction: Alzheimer’s disease (AD) vaccination is one of the last therapeutic options after two decades of stagnation in terms of drug development. About 140 (85%) immunization procedures against Aβ deposition and 25 (15%) against Tau have been reported, but no Food and Drug Administration approval of any AD vaccine has been achieved. This might be attributed to deficient pathogenic targets, inappropriate models, defective immunotherapeutic procedures, and inadequate clinical trial design. Areas covered: The issues covered include the following: AD pathogenic mechanisms, rationale for active and passive immunization, vaccine targets, anti-Aβ/Tau vaccines, vaccine technologies, animal models, and clinical trials. Expert opinion: A vaccine against AD is technically feasible; however, important methodological aspects should be changed for a tentative clinical success, including (i) the development of multitarget AD immunotherapies; (ii) the optimization of antibody titers and epitopes; (iii) the pharmacogenetic/pharmacoepigenetic validation of the immunization procedure; (iv) the prophylactic treatment of genetically stratified patients at a pre-symptomatic stage; and (v) the definition of primary endpoints in prevention, based on objective/multifactorial biomarkers. Even with exquisite protocols, a successful vaccine would be potentially useful in at most 20–30% of defined cases, according to the genetic, epigenetic, and pharmacogenetic background of AD patients.Keywords
This publication has 19 references indexed in Scilit:
- Reduction of amyloid beta by Aβ3-10-KLH vaccine also decreases tau pathology in 3×Tg-AD miceBrain Research Bulletin, 2018
- Recent advancements toward therapeutic vaccines against Alzheimer’s diseaseExpert Review of Vaccines, 2018
- Have there been improvements in Alzheimer’s disease drug discovery over the past 5 years?Expert Opinion on Drug Discovery, 2018
- Principles of Vaccination2016
- Validating Immunotherapy in Alzheimer's Disease: The EB101 VaccineCurrent Pharmaceutical Design, 2016
- An anti-pyroglutamate-3 Aβ vaccine reduces plaques and improves cognition in APPswe/PS1ΔE9 miceNeurobiology of Aging, 2015
- Bapineuzumab: Anti-β-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer‘s DiseaseImmunotherapy, 2010
- Aβ Immunotherapy Leads to Clearance of Early, but Not Late, Hyperphosphorylated Tau Aggregates via the ProteasomeNeuron, 2004
- Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's diseaseNature, 2000
- Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouseNature, 1999